Comparative Pharmacology
Head-to-head clinical analysis: FESOTERODINE FUMARATE versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FESOTERODINE FUMARATE versus HICON.
FESOTERODINE FUMARATE vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), with highest affinity for M3 receptors; reduces detrusor muscle contractions and bladder overactivity.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
4 mg orally once daily; may be increased to 8 mg once daily based on tolerability.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5–10 hours) for the active metabolite (5-hydroxymethyl tolterodine, 5-HMT). The parent drug fesoterodine has a very short half-life (<1 hour) and is rapidly hydrolyzed to 5-HMT. Clinical context: steady-state achieved within 2–4 days of b.i.d. dosing.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Primary route is renal (70% of administered dose as metabolites, 7% as unchanged drug). Hepatic metabolism with biliary/fecal elimination accounts for ~23% (primarily via CYP2D6 and CYP3A4).<|im_end|>
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category A/B
Category C
Anticholinergic
Anticholinergic